Zynerba Pharmaceuticals Stock News

– RECONNECT, a confirmatory pivotal trial of Zygel™ in patients with FXS, expected to be initiated in the third quarter of 2021 –

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has received guidance from the US Food and Drug Administration (FDA) on a confirmatory Phase 3 trial of Zygel in patients with Fragile X syndrome (FXS).  The

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters at the

DEVON, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare

ZYNE has a cannabidiol gel it is running through various trials. The company and this drug have a history of failures.

SAN DIEGO, March 28, 2021 /PRNewswire/ -- Johnson Fistel, LLP is investigating potential claims on behalf of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) ("Zynerba " or the "Company") against certain

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will co

Developing novel transdermal CBD treatments to treat patients suffering rare epilepsies and neurological disorders Lead development candidate Zygel offers a potential goldmine of therapies for multipl

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) (FRA:6ZY) believes its operations and capital requirements to be fully funded into 2024, the company announced as part of its fourth-quarter and full-year res

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) believes its operations and capital req[uirements to be fully funded into 2024, the company announced as part of its fourth quarter and full-year results publ

DEVON, Pa., March 10, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare

Zynerba Pharmaceuticals (ZYNE) closed at $4.15 in the latest trading session, marking a +1.47% move from the prior day.

DEVON, Pa., March 04, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare

Zynerba Pharmaceuticals (ZYNE) closed at $4.50 in the latest trading session, marking a +0.78% move from the prior day.

ZYNE stock is on a roll, with investors betting its transdermal therapeutic cannabidiol gel will take off soon. The post ZYNE Stock: Why Zynerba Pharmaceutical Shares Are Soaring Today appeared first